These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 36719097)

  • 101. Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease.
    Kim DL; Lee SE; Kim NH
    Endocrinol Metab (Seoul); 2023 Feb; 38(1):43-55. PubMed ID: 36891650
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.
    Lv R; Xu L; Che L; Liu S; Wang Y; Dong B
    Front Endocrinol (Lausanne); 2023; 14():1125693. PubMed ID: 36860374
    [TBL] [Abstract][Full Text] [Related]  

  • 103. [Finerenone cardiorenal effects and its placement in treatment of chronic kidney disease in patients with type 2 diabetes mellitus: A review].
    Salukhov VV; Shamkhalova MS; Duganova AV
    Ter Arkh; 2023 Apr; 95(3):261-273. PubMed ID: 37167149
    [TBL] [Abstract][Full Text] [Related]  

  • 104. The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction.
    Kintscher U; Edelmann F
    Cardiovasc Diabetol; 2023 Jun; 22(1):162. PubMed ID: 37386461
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Mineralocorticoid Receptor Antagonists for Preventing Chronic Kidney Disease Progression: Current Evidence and Future Challenges.
    Fujii W; Shibata S
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175424
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Therapeutic Advances in Diabetic Kidney Disease.
    Georgianos PI; Vaios V; Eleftheriadis T; Papachristou E; Liakopoulos V
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769113
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.
    Sarafidis P; Agarwal R; Pitt B; Wanner C; Filippatos G; Boletis J; Tuttle KR; Ruilope LM; Rossing P; Toto R; Anker SD; Liu ZH; Joseph A; Ahlers C; Brinker M; Lawatscheck R; Bakris G;
    Clin J Am Soc Nephrol; 2023 May; 18(5):602-612. PubMed ID: 36927680
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
    Agarwal R; Pitt B; Rossing P; Anker SD; Filippatos G; Ruilope LM; Kovesdy CP; Tuttle K; Vaduganathan M; Wanner C; Bansilal S; Gebel M; Joseph A; Lawatscheck R; Bakris GL
    JAMA Cardiol; 2023 Aug; 8(8):732-741. PubMed ID: 37314801
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Nonsteroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection Is a New Option for Patients with Chronic Kidney Disease.
    Liu W; Yu S
    Kidney Dis (Basel); 2023 Jan; 9(1):12-25. PubMed ID: 36756081
    [TBL] [Abstract][Full Text] [Related]  

  • 110. [Finerenone].
    Vachek J; Tesař V
    Vnitr Lek; 2023; 69(E-3):20-23. PubMed ID: 37468332
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone.
    Ortiz A; Alcázar Arroyo R; Casado Escribano PP; Fernández-Fernández B; Martínez Debén F; Mediavilla JD; Michan-Doña A; Soler MJ; Gorriz JL
    Expert Rev Clin Pharmacol; 2023; 16(6):519-531. PubMed ID: 37190957
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR).
    Tanaka A; Shibata H; Imai T; Yoshida H; Miyazono M; Takahashi N; Fukuda D; Okada Y; Teragawa H; Suwa S; Kida K; Moroi M; Taguchi I; Toyoda S; Shimabukuro M; Tanabe K; Tanaka K; Nangaku M; Node K;
    Cardiovasc Diabetol; 2023 Jul; 22(1):194. PubMed ID: 37525257
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Therapeutic perspective: evolving evidence of nonsteroidal mineralocorticoid receptor antagonists in diabetic kidney disease.
    Yao L; Liang X; Wang P
    Am J Physiol Endocrinol Metab; 2023 Jun; 324(6):E531-E541. PubMed ID: 37166263
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Finerenone: Questions and Answers-The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist.
    Di Lullo L; Lavalle C; Scatena A; Mariani MV; Ronco C; Bellasi A
    J Clin Med; 2023 Jun; 12(12):. PubMed ID: 37373685
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888-897.
    Rossing P; Burgess E; Agarwal R; Anker SD; Filippatos G; Pitt B; Ruilope LM; Gillard P; MacIsaac RJ; Wainstein J; Joseph A; Brinker M; Roessig L; Scott C; Bakris GL;
    Diabetes Care; 2023 Sep; 46(9):1721. PubMed ID: 37310695
    [No Abstract]   [Full Text] [Related]  

  • 116. Therapeutic targeting of mineralocorticoid receptors in pulmonary hypertension: Insights from basic research.
    Mamazhakypov A; Lother A
    Front Cardiovasc Med; 2023; 10():1118516. PubMed ID: 36793473
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Update on Diabetic Kidney Disease (DKD): Focus on Non-Albuminuric DKD and Cardiovascular Risk.
    Scilletta S; Di Marco M; Miano N; Filippello A; Di Mauro S; Scamporrino A; Musmeci M; Coppolino G; Di Giacomo Barbagallo F; Bosco G; Scicali R; Piro S; Purrello F; Di Pino A
    Biomolecules; 2023 Apr; 13(5):. PubMed ID: 37238622
    [TBL] [Abstract][Full Text] [Related]  

  • 118. The cardio-renal-metabolic connection: a review of the evidence.
    Marassi M; Fadini GP
    Cardiovasc Diabetol; 2023 Jul; 22(1):195. PubMed ID: 37525273
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction.
    Lima-Posada I; Stephan Y; Soulié M; Palacios-Ramirez R; Bonnard B; Nicol L; Kolkhof P; Jaisser F; Mulder P
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768859
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Management of Type 2 Diabetic Kidney Disease in 2022: A Narrative Review for Specialists and Primary Care.
    Cherney DZI; Bell A; Girard L; McFarlane P; Moist L; Nessim SJ; Soroka S; Stafford S; Steele A; Tangri N; Weinstein J
    Can J Kidney Health Dis; 2023; 10():20543581221150556. PubMed ID: 36726361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.